A continuing controversy: magnesium sulfate in the treatment of eclamptic seizures.
It would appear from the above that Pritchard agrees with the use of some agents other than magnesium sulfate that have known anticonvulsant properties. We believe that the subject at issue is whether magnesium sulfate should be used in treating the seizures of eclampsia. In our "Controversies" article, we do not address the issue of whether magnesium sulfate modifies pathophysiological factors leading to preeclampsia, but restrict ourselves to the treatment of the seizure per se, once seizures supervene, and the avoidance of their recurrence. The pathophysiological mechanisms and optimal treatment of preeclampsia and of eclampsia (excepting seizures) remain to be determined, as does the use of magnesium sulfate in this condition. Eclamptic seizures are clinically and electroencephalographically indistinguishable from generalized tonic-clonic seizures. Whether seizures arise in or out of the setting of preeclampsia, they should be treated as are other seizures, with known anticonvulsants. Controlled clinical trials are needed to address the effectiveness of alternative antiseizure regimens.
Department of Neurology, Francis Scott Key Medical Center, Baltimore, MD 21224.
P W
PW
Kaplan
R P
RP
Lesser
R S
RS
Fisher
J T
JT
Repke
D F
DF
Hanley
D004461:Eclampsia / Q000150:complications*; D005260:Female; D006801:Humans; D008278:Magnesium Sulfate / Q000627:therapeutic use*; D010672:Phenytoin / Q000627:therapeutic use; D011247:Pregnancy; D012640:Seizures / Q000188:drug therapy* / Q000209:etiology
D010672:Phenytoin; D008278:Magnesium Sulfate